New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - clonidine 7.5mg - transdermal patch - 7.5 mg - active: clonidine 7.5mg excipient: calcium stearate - catapres-tts is indicated for the treatment of mild to moderate hypertension. it can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - bovine lung lipids 25 mg/ml (total phospholipids); colfosceril palmitate 11 mg/ml - 15.5 mg/ml (disaturated phosphatidylcholine); palmitic acid 1.4 mg/ml - 3.5 mg/ml (free fatty acid); tripalmitin 0.5 mg/ml - 1.75 mg/ml (triglycerides) - intratracheal suspension - 25 mg/ml - active: bovine lung lipids 25 mg/ml (total phospholipids) colfosceril palmitate 11 mg/ml - 15.5 mg/ml (disaturated phosphatidylcholine) palmitic acid 1.4 mg/ml - 3.5 mg/ml (free fatty acid) tripalmitin 0.5 mg/ml - 1.75 mg/ml (triglycerides) excipient: sodium chloride water for injection - survanta is indicated for prevention and treatment ("rescue") of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants. survanta significantly reduces the incidence of rds, mortality due to rds and air leak complications.

Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol uk limited - xylazin hydrochloride - solution for injection - 20 mg/ml - xylazine - bovine, canine, equine - food, feline - neurological preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

cp-pharma handelsgesellschaft mbh - xylazin hydrochloride - solution for injection - 20 mg/ml - neurological preparations - bovine canine equine - food feline

Singapore - English - HSA (Health Sciences Authority)

biomedical strategy consultants pte ltd - nitric oxide - gas - 800ppm

European Union - English - EMA (European Medicines Agency)

linde healthcare ab - nitric oxide - hypertension, pulmonary; respiratory insufficiency - other respiratory system products - inomax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.

Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol uk limited - xylazine - solution for injection - 20 milligram(s)/millilitre - xylazine - cats, cattle, dogs, horses - neurological preparations

New Zealand - English - Ministry for Primary Industries

akorn animal health nz ltd - xylazine present as xylazine hydrochloride - xylazine present as xylazine hydrochloride 20 g/litre - analgesic

New Zealand - English - Ministry for Primary Industries

dechra veterinary products nz limited - xylazine - xylazine 20 g/litre - sedative

Canada - English - Health Canada

laboratoire riva inc. - ranitidine (ranitidine hydrochloride) - tablet - 75mg - ranitidine (ranitidine hydrochloride) 75mg - histamine h2-antagonists